PARP1 and cancer: Decades later, a screen of hundreds of cancer cell lines seeking to identify biomarkers for targeted cancer agents discovered EWSR1::FLI1 was significantly associated with sensitivity to the PARP [Poly (ADP-ribose) polymerase] inhibitor (PARPi) olaparib (19).